Biopatid (Biopatid)
A product by UNIKKA PHARMA (distributed by Biopell Medical) that claims tirzepatide as its active ingredient. Mechanism of action, dosing, transparent comparison with Mounjaro and Ozempic.
What Is Biopatid?
Biopatid is a product that claims tirzepatide as its active ingredient. Manufactured by UNIKKA PHARMA (LCA Farmacêutica LTDA, Brazil), distributed by Biopell Medical.
Tirzepatide is a dual GLP-1 and GIP receptor agonist developed by Eli Lilly (Mounjaro, Zepbound). Biopatid is not an original product by Eli Lilly. Eli Lilly officially states that it does not supply tirzepatide to third-party manufacturers.
Biopatid is available in 40 mg and 60 mg vials. The client independently draws the required dose from the vial. Dosing is analogous to Mounjaro — starting at 2.5 mg with gradual increases under specialist supervision.
Biopatid is not registered in the State Register of Medicines of Ukraine and has not undergone its own randomized clinical trials.
Key Facts
How Biopatid Works for Weight Loss
According to the manufacturer, Biopatid contains tirzepatide — a molecule that activates two receptors (GLP-1 and GIP). The mechanism of action is described based on studies of the original tirzepatide by Eli Lilly.
Appetite Reduction
Acts on hunger and satiety centers in the hypothalamus. You naturally eat less — without willpower or calorie counting.
Prolonged Satiety
Slows gastric emptying, extending the feeling of fullness after meals. Portions decrease naturally, snacking disappears.
Dual Metabolism
GLP-1 improves glucose metabolism, GIP enhances fat burning. Dual action = more pronounced results compared to single agonists.
Results and Efficacy
Clinical Data for Tirzepatide (Eli Lilly)
Biopatid by Biopell Medical claims tirzepatide as its active ingredient. Tirzepatide is a molecule developed by Eli Lilly, confirmed by large-scale SURMOUNT studies. In SURMOUNT-1 (2,539 participants, 72 weeks), participants on the maximum dose (15 mg) lost an average of 20.9% body weight (ITT analysis, NEJM).
* The SURMOUNT-1 study was conducted for Mounjaro by Eli Lilly. Biopatid has not undergone its own clinical trials. Eli Lilly states it does not supply tirzepatide to third-party manufacturers. Biopell Medical data: -22% body weight over course, 94% of patients remain on program after 6 months.
DOZA client results: most clients on Biopatid report reduced appetite from the first days. Real cases — on the Biopatid results page.
Expected Timeline (per manufacturer claims)
- • Week 1: appetite decreases (per Biopell Medical data)
- • Week 2: hunger levels stabilize
- • Weeks 3–4: potential weight loss begins
- • 3+ months: 0.5–1 kg/week (Biopell Medical claim, not confirmed by RCTs)
Per Biopell Medical data
Advantages of Dual Action
- • GLP-1 + GIP — dual mechanism for appetite control
- • Claims the same active ingredient as Mounjaro (tirzepatide)
- • Part of the Biopell Medical system
Biopatid Dosing
The dosing regimen mirrors Mounjaro — starting at 2.5 mg with gradual increases. Available in vials (not pen injectors); the client draws the dose independently.
Biopatid is available in 40 mg and 60 mg vials. Dosing starts at 2.5 mg with gradual increases — same as Mounjaro. The client independently draws the required dose from the vial.
Adaptation Profile
Biopatid has not conducted its own safety studies. Below is the general tirzepatide profile based on SURMOUNT-1 data (Mounjaro, Eli Lilly).
A DOZA specialist supports the entire adaptation process and helps minimize any discomfort. Consultation — via Telegram.
DOZA Transparency Regarding Biopatid
Biopatid is not an original medication. The tirzepatide molecule was developed by Eli Lilly (Mounjaro, Zepbound). Biopatid is manufactured by UNIKKA PHARMA (LCA Farmacêutica LTDA, Brazil) — a third-party company not affiliated with Eli Lilly.
Eli Lilly's position: Eli Lilly officially states that it does not supply the active pharmaceutical ingredient (API) tirzepatide to any third-party manufacturers.
No registration: Biopatid is not registered in the State Register of Medicines of Ukraine. No product containing tirzepatide as an active ingredient is registered in Ukraine as of 2026.
No proprietary clinical trials: Biopatid has not undergone randomized clinical trials (RCTs). Efficacy data references SURMOUNT-1 — a study conducted by Eli Lilly for the original Mounjaro.
DOZA provides full transparency regarding product origin. Consult with your physician. Full analysis on the clinical research page →
Not Sure Which to Choose?
A DOZA specialist will help you select the optimal medication for your goals — considering efficacy, clinical evidence, and budget.
Biopatid vs Mounjaro vs Ozempic
| Parameter | Biopatid | Mounjaro | Ozempic |
|---|---|---|---|
| Manufacturer | UNIKKA PHARMA (Brazil) | Eli Lilly (USA) | Novo Nordisk (Denmark) |
| Active ingredient | Tirzepatide (claimed) | Tirzepatide | Semaglutide |
| Mechanism of action | GLP-1 + GIP | GLP-1 + GIP | GLP-1 only |
| Efficacy (RCTs) | No proprietary RCTs* | -20.9% (SURMOUNT-1) | -14.9% (STEP-1) |
| Formulation | Vials 40/60 mg | KwikPen | FlexTouch pen |
| Dosing | From 2.5 mg (same as Mounjaro) | 2.5–15 mg | 0.25–2 mg |
| Frequency | 1× per week | 1× per week | 1× per week |
| Tolerability | No proprietary data | Discomfort in 5–10% | Discomfort in 10–15% |
| Clinical trials | None proprietary | SURMOUNT, SURPASS | STEP, SUSTAIN |
| FDA/EMA registration | ❌ No | ✅ FDA 2022, EMA 2022 | ✅ FDA 2017, EMA 2018 |
| Ukraine State Register | ❌ Absent | ❌ Absent | ❌ Absent |
* Biopatid has not undergone its own RCTs. Efficacy data is based on SURMOUNT-1 (Eli Lilly study for the original Mounjaro). Eli Lilly states it does not supply tirzepatide to third-party manufacturers.
Full Biopatid analysis → · Mounjaro vs Ozempic: comparison
📚 Sources
- • SURMOUNT-1 (NEJM, 2022) — Tirzepatide for weight management, 2539 participants, 72 weeks, -20.9% (15 mg, ITT)
- • STEP-1 (NEJM, 2021) — Semaglutide 2.4 mg for weight management, 1961 participants, 68 weeks
- • FDA: Tirzepatide approved for chronic weight management (2023); Semaglutide — Ozempic (2017), Wegovy (2021)
Frequently Asked Questions About Biopatid
Biopatid is a product that claims tirzepatide as its active ingredient. Manufactured by UNIKKA PHARMA (Brazil), distributed by Biopell Medical. It is not an original product by Eli Lilly — the developer of the tirzepatide molecule. Available in 40 mg and 60 mg vials for weekly use. Not registered in the State Register of Medicines of Ukraine.
DOZA Specialist
Take a free test
2 minIn 2 minutes, find out which program suits you best. Personalized weight loss and cost estimate.
See Also
Mounjaro Catalog
Original tirzepatide by Eli Lilly · FDA 2022
Biopatid Catalog
Check availability and pricing
Mounjaro vs Ozempic
Detailed comparison: -20.9% vs -14.9%
Weight Loss with DOZA
All weight loss methods and programs
GLP-1 Medications — Complete 2026 Table
Comparison of all GLP-1 medications in Ukraine
Ozempic Alternatives in Ukraine 2026
What to choose instead of semaglutide — alternatives
Weight Loss Products 2026 — Market Overview
From supplements to GLP-1: what actually works